Abstract Bisphosphonates such as alendronate, risedronate and zoledronate have revolutionised the treatment for
Bisphosphonates in non-malignant bone disease
Osteoporotic fractures are a major public health problem in most Western countries. Patients sustaining a hip fracture have a 33 % mortality rate in the following 12 months [1, 2] . This excess mortality may persist for up to 10 years following fracture [3, 4] . Up to one-third of such patients subsequently require admission to residential care [5] .
Bisphosphonates (BPs) such as alendronate (ALN), risedronate (RSD), ibandronate and zoledronate (ZLD) are first-line treatments for osteoporosis, especially following low-trauma fracture [6] . In Australia (population 22.5 million people), 1.3 million BP scripts were written for the treatment for osteoporosis in the 12 months from July 2009 to June 2010. This is similar to the number of prescriptions for celecoxib, a cyclo-oxygenase-2 inhibitor used for symptom relief in arthritis and budesonide, a common inhaled corticosteroid used for asthma [7] . Paget's disease is another common benign bone disorder for which BPs are indicated [8] .
Of the available BPs, ZLD appeared to offer the greatest protection against fracture [9] . Annual intravenous (IV) ZLD in post-menopausal women was well tolerated and increased bone mineral density (BMD) by up to 5 % at 12 months and lowered the risk of vertebral and hip fracture over 3 years [10, 11] . An additional 3 years of ZLD maintained the initial BMD gain [12] . Zoledronate administration within 90 days following surgical repair of a fractured hip reduced the risk of another fracture and improved patient survival-possibly due to a beneficial effect on cardiovascular events and pneumonia [13, 14] . The decline in hip fracture incidence in the USA occurred in parallel with increased BP use [15] . Australian data suggested oral BPs were associated with a lower mortality rate in women and men compared to those on no treatment [16] .
A succession of case reports since 2003 highlighted the possible association between BPs, especially ZLD or pamidronate (APD), and ONJ [17] [18] [19] [20] [21] [22] [23] . However, the American Society of Bone and Mineral Research (AS-BMR) noted the quality of reported evidence was often poor [24] . Incomplete patient data, lack of prospective patient follow-up and incomplete reporting of BP parameters made accurate estimation of ONJ prevalence difficult [25, 26] . ONJ has been the subject of much media attention, capturing public imagination and resulting in at-risk patients refusing BPs [27] . This paper seeks to provide treating clinicians with a balanced multi-disciplinary review of the available evidence pertaining to this issue and practical advice regarding prevention and management of ONJ.
Methods
We identified published studies by performing a computerised literature search of the PubMed database using the key words ''bisphosphonate'' and ''dental'' or ''jaw'' for English language papers published during the last 10 years. All key articles were retrieved with articles in all journals considered. Reference lists of published papers were explored to identify additional relevant papers. The authors independently reviewed and judged the selected publications on their contribution to knowledge on the topic and then reached a consensus on which publications to include in this review. As previously noted by the ASBMR, the quality of reported evidence was often poor [24] . All papers were Level III or IV evidence-case-control studies or case series, respectively.
Diagnosis of ONJ
The American Association of Oral and Maxillofacial Surgeons (AAOMS) proposed a definition of ONJ as ''exposed necrotic bone in the maxillofacial region that has persisted for more than 8 weeks'' in the absence of a history of radiation therapy to the jaw (Fig. 1) [28, 29] . The ASBMR and a European Working Group also suggested an 8-week cut-off as trauma, extractions and oral surgical procedures are usually followed by tissue healing within this time [24, 30] . The ASBMR guidelines highlighted several important differential diagnoses including periodontal disease, gingivitis, mucositis, osteomyelitis, sinusitis, temporo-mandibular joint disease, osteoradionecrosis and bone tumours [24] . The possible features of BP-related ONJ (BRONJ) are outlined in Table 1 [24, [31] [32] [33] [34] . However, as none of these are specific for ONJ, a careful medical and dental history is crucial-especially the dose/duration of BP therapy and presence of preceding dental trauma. Radiographs are essential to exclude alternative diagnoses such as malignancy [34] .
Pathogenesis of ONJ
Bisphosphonates are preferentially deposited in bone where they inhibit osteoclast activation and promote osteoclast apoptosis by several mechanisms including inhibition of protein prenylation and blockade of mevalonate metabolism [35] [36] [37] . BPs appear anti-angiogenic [38] [39] [40] and may inhibit matrix metalloproteinases (the enzymes involved in tumour metastasis and connective tissue remodelling) [41, 42] and in vitro proliferation of oral keratinocytes [41] . Once taken up by bone, BPs are usually eliminated during bone resorption-a process taking some years [43] . This results in a long bone half-life, for example up to 10 years for ALN [44] . Differences in binding affinities of the various BPs for hydroxyapatite affect release from bone and may explain the observed clinical differences in potency, pharmacokinetics and duration of effect [45] .
Mucosal damage following extraction, irritation from ill-fitting dentures or insertion of dental implants complicated by infection and bone necrosis in the setting of BPinduced low bone turnover may contribute to ONJ. BPs may exert an inhibitory effect on oral epithelial growth [46] . In vitro work using human gingival fibroblast and keratinocyte cell lines found ZLD inhibited cellular proliferation and promoted apoptosis [47] . These findings may explain the upper gastrointestinal side effects seen with orally administered BPs and the oral ulceration described Fig. 1 Osteonecrosis of the maxilla in a 51-year-old female patient with Goodpasture's syndrome who had undergone a cadaveric renal transplant 15 years earlier. She had been taking alendronate 70 mg weekly for 4 years for glucocorticoid-induced osteoporosis and presented 4 months following multiple dental extractions with painful areas of non-healing exposed bone (arrow). There was no history of radiotherapy to the area following chewing of BP tablets [46, 48] . Various disease states such as diabetes, renal failure or immunosuppression may impair tissue healing and result in infection. Due to their highly polar nature, oral BPs are poorly absorbed from the gastrointestinal tract and therefore have low bioavailability-often less than 2 % [49, 50] . Oral BPs also have lower potency; for example, ALN and RSD are approximately 30-50 times less potent than ZLD [51] . The higher bioavailability and potency of IV BPs may explain their stronger association with ONJ. However, it is for these very reasons and the convenient mode of administration that IV BPs are used.
Detailed histomorphometric analysis of jaw bone samples from patients with probable BRONJ (26/31 with an underlying malignancy) revealed little osteoclastic activity or new bone formation compared to corresponding samples from controls [32] . Bone obtained from cases appeared thicker and less vascular-especially in the setting of infection.
While osteonecrosis may occur at other anatomic sites, for example the femoral head or femoral condyle, these sites are sterile and therefore do not progress to persistent frank bone necrosis. In contrast, the mouth is a unique anatomic site because abundant micro-organisms have ready access to bone [23, 52] . Furthermore, jaw bones undergo repeated trauma from masticatory activity [53] and have an extensive blood supply allowing BPs to achieve high local concentrations [54, 55] .
The central role of osteoclast inhibition in the pathogenesis of ONJ is supported by recent case reports of a similar complication in patients receiving denosumab, a monoclonal antibody blocking receptor activator of nuclear factor kappa-B ligand (RANKL), a crucial cytokine promoting osteoclastogenesis [56, 57] . Most of these cases have been described in patients with an underlying malignancy receiving large doses of denosumab (120 mg s/c every 4 weeks). No cases of ONJ were reported in the pivotal FREEDOM study of 7,868 women with post-menopausal osteoporosis (PMO) treated with denosumab (60 mg s/c every 6 months) for 3 years [58] . Two cases of ONJ, both of which subsequently healed, were reported in the 5-year study extension [59] .
Animal models of ONJ Development of a suitable animal model would assist clarification of the pathogenesis and treatment for ONJ. Several rat models of BRONJ have been reported [60] [61] [62] [63] . Extraction of an upper molar tooth was performed in Wistar rats following weekly administration of ZLD (0.04 mg IV weekly for 5 weeks). Seven weeks postextraction, all rats treated with ZLD showed expansion of the surgical defect and exposed bone. Irregularity of the cortical margin and bone destruction was noted while histologic analysis of the defect revealed necrotic bone with osteocyte loss [60] . Another study involving rats compared the risk of jaw necrosis post-dental extraction following administration of ALN (0.05 mg/kg weekly by gavage) or ZLD (0.6 mg/kg intra-peritoneally weekly). Eighty per cent of rats given ZLD had histologic osteonecrosis while no changes were seen following ALN or in controls [61] . Rats administered ZLD at a dose of 7.5 mcg/kg once a week for up to 3 weeks and dexamethasone prior to molar extraction developed ulceration with underlying areas of necrotic bone [62] . However, the above ZLD regimes were more analogous to the large doses seen in oncology rather than the smaller doses used for non-malignant bone disease [60] [61] [62] .
Others have suggested a canine model of ONJ may be more appropriate as canine bone turnover is more similar to that seen in humans [64, 65] . The recent development of murine models of BRONJ is exciting as this will allow access to the extensive experimental tools and well-defined immunology of genetically altered mice [66, 67] . However, caution needs to be exercised in extrapolating data from animal studies to humans as there are considerable differences in bone remodelling and oral function. Bisphosphonates and ONJ Previously, clinically similar but less frequent presentations occurred following radiotherapy (Fig. 2) or occupational exposure to phosphorus [19, 68] . ONJ appears mainly in the setting of malignancy, especially multiple myeloma [69] [70] [71] or breast cancer [20] [21] [22] 72] -possibly due to the greater cumulative doses of BP used to treat these cancers [73] . In myeloma patients, IV ZLD and APD were associated with a 10 and 3 % incidence of ONJ at 36 months, respectively [70] . A longitudinal cohort study examined 1,621 patients who received 29,006 doses of IV BP and found the crude incidence of ONJ was 8.5, 3.1 and 4.9 % in patients with myeloma, breast cancer and prostate cancer, respectively [74] . However, a retrospective study of 2,239 cancer patients suggested a lower prevalence (1.3 %) of BRONJ [73] . A systematic review identified 99 cases of ONJ in patients treated with a BP for non-malignant bone disease [75] . Eighty-nine per cent of cases with a recorded dental history underwent a preceding dental procedure; 71 % of cases were taking at least one bone-active medication (usually a corticosteroid) in addition to the BP while 81 % of patients had additional comorbid conditions such as rheumatoid arthritis and diabetes predisposing to poor wound healing [75] . Review of 119 patients with probable BRONJ suggested the mean time to clinical presentation was 14.3 months for APD, 9.4 months for ZLD and 3 years for those receiving ALN [54] . Almost all these patients were treated with IV BPs for malignant bone disease, and ONJ appeared to be precipitated by dental trauma, for example tooth extraction or ill-fitting dentures [17, [19] [20] [21] . Coexistent periodontitis, a bacterial plaque-related disease resulting in gingival inflammation and alveolar bone resorption, was often noted [54] . However, potential confounders, for example chemotherapy, radiotherapy, corticosteroid use and dental/ sinus infections, complicated attribution of causality [76] . A retrospective analysis of 4,019 cancer patients treated with IV BPs identified high cumulative BP dose, poor oral health and dental extraction as risk factors for ONJ [73] while others have suggested a possible association with diabetes [77] .
Bisphosphonates and ONJ in non-malignant bone disease
There appear markedly fewer cases of ONJ during treatment with BPs for osteoporosis [19, 22, 54, 78, 79] . However, a recent study reported 135 consecutive patients from June 2005 to May 2009 with probable BRONJ [80] . Twenty-five of these patients were treated for osteoporosis with a mean duration of BP therapy of 50 months [80] . Review of patients at a single academic dental centre identified 208 patients with a history of ALN use [81] . Of these, nine (4 %) had ONJ-all following tooth extraction or other dental trauma resulting in bone exposure. In comparison, of the 13,522 patients at the same centre without a recorded history of ALN use, 4,384 (32 %) underwent dental extraction with no reported ONJ. A retrospective study from 11 different European centres reported 47 cases of probable BRONJ diagnosed between 2004 and 2008 [82] . Eight per cent (37/470) of cases appeared to be associated with BP therapy for osteoporosis with a mean duration of oral BP use of 57.8 ± 5.3 months [82] .
A study of patients with PMO receiving ALN for up to 10 years reported no cases of ONJ [83] . No BRONJ cases were reported from the risedronate and alendronate clinical trials (each involving 16,000-17,000 patients) [84] . A systematic literature review found incidence rates for BRONJ among patients with OSP varied from 0.028 to 4.3 % [85] . A nested case-control study within a cohort of six million individuals aged [55 years from an Italian Clinical assessment revealed a history of radiotherapy to the orofacial region for previous malignancy claims database found an adjusted OR for ONJ in current BP users was 2.8 (95 % CI 1.3-5.9) against never users [86] . The American Dental Association (ADA) concluded the risk of ONJ in patients taking oral BPs was considerably less compared to that seen following IV BP for malignancy [87] . A double-blind placebo-controlled trial of 3,889 patients with PMO who received three infusions of ZLD over a 2-year period reported no ONJ cases [11] . Blinded adjudication of the database subsequently yielded one case each of delayed dental healing in the ZLD and control groups. Both cases occurred following dental manipulation and resolved with antibiotics and debridement [11] . No further ONJ cases were reported in the 3-year extension of this study nor following review of data from four other clinical trials involving patients with low BMD treated with ZLD [12, 88] .
While there may be less published evidence that chronic low-dose BP therapy for osteoporosis or other non-malignant bone disease is associated with ONJ, this may change as more people are treated for longer periods of time with these agents. The lack of ONJ cases reported from the ALN and RSD clinical trial programmes suggests a low frequency of this complication. There may also be a long latency of onset due to the relatively low doses of oral BP administered during the trial. Furthermore, delayed dental healing/ONJ was not one of the secondary outcomes specifically captured during these trials. Patients with nonmalignant bone disease usually live longer than those with an underlying malignancy, making them candidates for a drug-related complication with a long latency of onset. As BPs have a long in vivo half-life of up to a decade [89, 90] and ALN suppressed bone turnover markers for up to 5 years following cessation [83] , it is possible that increasing numbers of patients will present with delayed dental healing over the next few years. It is difficult to extrapolate findings from the oncologic literature to nonmalignant bone disease as BP doses for malignant bone disease are up to tenfold higher than those used in osteoporosis, for example ZLD 4 mg IV 4 weekly [90] and ZLD 4 mg IV annually [10] , respectively. The exact risk of ONJ in non-malignant bone disease is uncertain. Australian data acquired via postal survey of oral and maxillofacial surgeons suggested a risk as high as 1:2,260-1:8,460 in patients taking weekly ALN for osteoporosis [91] . However, the retrospective study design and lack of adjudicated diagnosis may have resulted in referral/recall bias and uncertain case definition-thus elevating the risk. The ASMBR suggested a more conservative risk estimate of 1:10,000-1:100,000 for patients with osteoporosis taking BPs [24] .
A retrospective study using data from two Health Maintenance Organizations (HMO) attempted to assess the incidence of ONJ and estimate odd ratios (OR) for ONJ risk following BP exposure [92] . Twenty-three cases of ONJ were identified from 572,606 members with a calculated incidence of 0.63 (95 % CI 0.39-1.59) per 100,000 person-years. However, study limitations included the quality of data entered in the electronic medical record, lack of a specific diagnostic code for ONJ and recall bias by treating clinicians. With these caveats, the ORs (95 % CI) of ONJ associated with the following risk factors were as follows: oral BP use 9.2 (3.6-23.3), head/neck radiation 14.2 (4.8-41.6), any cancer 7.6 (3.4-17.3), corticosteroids 3.0 (1.3-6.8) and diabetes 1.6 (0.5-4.6) [59] . A casecontrol study (n = 308 cases) involving patients from US community-based dental practices found that BP use for more than 2 years, oral suppuration and dental extractions were independent risk factors for ONJ [93] . In cases with non-malignant bone disease, BP use less than 2 years, 2-5 years and more than 5 years had OR (95 % CI) of 5.2 (1.2-22.5), 11.4 (3.2-40.2) and 26.6 (5.3-133.6), respectively [93] . In another study, 13,946 HMO members taking oral BPs were contacted by mail. Of the 8,572 respondents, 2,159 reported relevant dental symptoms. Of these, 1,005 agreed to a dental examination and nine cases of ONJ were identified, yielding a prevalence of 0.10 % [94] .
A retrospective cohort study of 30 cases of BRONJ all of whom had received oral BP for osteoporosis found that healing was slower in those developing BRONJ following dental extraction especially in the presence of comorbidities such as rheumatoid arthritis, diabetes, glucocorticoid therapy and disease-modifying anti-rheumatic drugs [95] .
A case-control study to assess the risk of ONJ in Australian patients receiving BP for non-malignant bone disease has been performed [96] . The primary outcome was the incidence of delayed dental healing occurring either spontaneously or following dental procedures [96] . Study results will assist in clarifying the risk of delayed dental healing following BP use in patients with non-malignant bone disease and in controls. Unfortunately, the risk of delayed dental healing/exposed bone in the absence of BP use is not definitively known. This has hampered attribution of causality as exposed oral bone in the maxillofacial region which fails to heal despite conservative measures has also been reported in the absence of BP exposure [24, 97] .
Prevention of ONJ
Although published guidelines regarding prevention of and treatment for ONJ exist, they are based on expert opinion rather than firm data [28, 87, [98] [99] [100] . While there remains much uncertainty among the dental, oral surgical and medical professions regarding optimal dental management of patients prior to and during BP therapy, these guidelines have encouraged dialogue between specialties. A staging system developed by AAOMS should assist classification of severity and standardisation of communication (Table 2 ) [29, 55] .
It seems sensible to arrange dental review prior to BP commencement so any invasive dental procedures can be performed [29, 34, 53] . The ADA suggests routine dental care should not be modified solely because of coexistent oral BP use [87] . Dentures should be checked to ensure they are well fitting and areas of denture trauma identified. This is a good opportunity to educate patients regarding dental hygiene and the need for regular dental care as they are often poorly informed about the reason for BP therapy and the possible impact on dental health [101] . Patients should be instructed to promptly report any new dental symptoms, especially dental pain, swelling or exposed bone. During BP therapy, active early treatment for dental infection should be undertaken and invasive dental therapy performed only if necessary, and in consultation with the treating medical practitioner. Implementation of such preventive measures and delaying ZLD administration for 6-8 weeks following invasive dental procedures to allow wound healing reduced the risk of ONJ in oncological patients [102, 103] . No data suggest BP cessation prior to invasive dental surgery influences outcome [23, 30] . This should be determined on a case-by-case basis upon an assessment of current fracture risk and following consultation between members of the treating team [104] . The prolonged suppression of bone turnover following cessation of ALN [83] means stopping it for even months prior to any invasive dental procedure may not have a meaningful biologic effect. In contrast, the shorter in vivo halflife of RSD suggests its cessation for some months prior to any invasive dental procedure may be appropriate [51] .
A recent prospective study involving 700 consecutive patients taking oral BPs for osteoporosis who underwent a total of 1,480 dental extractions found that antibiotic coverage in combination with either delicate surgery and closure by primary intention or non-traumatic avulsion and closure by secondary intention resulted in no cases of BRONJ [105, 106] .
An uncontrolled retrospective study in patients with osteoporosis suggested a greater risk of ONJ in those with a more suppressed serum C-telopeptide (CTx), a marker of bone resorption [105, 106] . However, the level of serum CTx identified in this paper as ''high risk'' for development of ONJ is seen in many patients after 3 years of ALN [107] . Furthermore, the presence of a low serum CTx following annual IV ZLD in patients with PMO was not associated with a high risk of ONJ [11, 88] . Other work has failed to validate the utility of CTx as a useful predictive biomarker of ONJ [108] . Overall, the evidence for a strong correlation of ONJ risk with serum CTx levels is dubious and the ASBMR has advised this biomarker is not useful in assessing ONJ risk [109] .
Management of ONJ
Once ONJ has developed, therapy involving local debridement, irrigation and antibiotics is usually unsuccessful due to difficulty obtaining an acceptable surgical margin manifested by viable bleeding bone [54, 110] . Surgical debridement often contributes to tissue breakdown resulting in fistulae and morbidity including halitosis and pain [54, 110] . Conservative therapy is preferable with strict control of infection using anti-microbial rinses or systemic antibiotics [24] . However, the outcome of ONJ in patients with benign compared to malignant bone disease may be better due to differences in type, dose and route of BP [33, 79, 111] . Where indicated, necrotic bone and sharp bone edges should be carefully removed under antibiotic cover with minimal tissue/bone trauma. Unlike osteoradionecrosis of the jaw and despite the presence of some case reports suggesting benefit, there is no clear evidence that hyperbaric oxygen promotes wound healing [24, 29, 112, 113] .
A case report described the successful use of teriparatide (recombinant human parathyroid hormone), a potent bone anabolic agent in promoting healing of the osseous defect in an elderly lady with ALN-related ONJ [114] . The stimulatory effect of teriparatide on bone remodelling may have been responsible for the observed rapid healing of the persistent mandibular bony defect. This finding has been reported by others [115] [116] [117] [118] . A randomised controlled study of 40 patients with severe chronic periodontitis found that daily teriparatide was associated with faster resolution Exposed/necrotic bone in patients with pain, infection and one or more of the following: pathologic fracture, extra-oral fistula, or osteolysis extending to the inferior border or sinus floor of dental osseous defects compared to placebo [118] . While these findings require validation in larger prospective controlled studies, they raise the possibility that stimulation of bone remodelling by teriparatide may be helpful in the treatment for ONJ.
Relationship of impaired dental healing to ONJ While ONJ is a devastating end-stage complication, impaired dental healing may be a less dramatic earlier, poorly recognised but more common complication of BP use. Small case series have suggested early BRONJ may present without exposed bone but with jaw bone pain, sinus tract and gingival swelling [119, 120] . A recent case series of 332 patients from five European centres identified 96 patients who presented with the ''non-exposed'' variant of ONJ [121] . Twenty-six per cent of these patients were being treated for osteoporosis with BPs [121] . While these patients would not fulfil the initial AAOMS or ASMBR definition of ONJ due to lack of exposed bone [24, 28] , they suggest an earlier form of ONJ. AAOMS has since introduced ''Stage 0'' ONJ-''No clinical evidence of necrotic bone'' (Table 2 ) [29] . Prompt detection of impaired dental healing is crucial as this may allow intervention with aggressive antibiotic therapy and/or dental hygiene strategies to prevent progression to frank ONJ.
Conclusion
Bisphosphonates have revolutionised the treatment of nonmalignant bone disease, especially osteoporosis. They reduce fracture risk and probably mortality in patients with osteoporosis. In comparison, the small risk of ONJ in such patients means the benefit:risk ratio is high, especially in those with previous low-trauma fracture or a T-score less than -2.5 [122] . While the exact risk of ONJ in patients using BP for non-malignant bone disease is uncertain, the publication of multiple management guidelines has increased awareness of this problem among clinicians. This should translate into timely identification and appropriate early management of new cases of ONJ, which may only become apparent over many years due to the long in vivo half-life of BPs and the increasing numbers of patients using these medications.
Key messages
• Bisphosphonates may be associated with delayed dental healing and osteonecrosis of the jaw.
• The risk of dental complications from bisphosphonates at the doses used for non-malignant bone disease is low.
It is much lower than that seen following their use in malignant bone disease. There are several reasons for this, including the substantially lower doses of bisphosphonate used in non-malignant bone disease.
• This low risk is further minimised by effective communication between the treating dental, surgical and medical health professionals. The risk:benefit ratio of bisphosphonates favours their use for the prevention of osteoporotic fractures.
